Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
PXRCKSV1pgeFd3kn
